Mauricio Jalife Bucay, MD | |
505 Parnassus Ave, San Francisco, CA 94143 | |
(415) 750-4994 | |
(415) 750-8156 |
Full Name | Mauricio Jalife Bucay |
---|---|
Gender | Male |
Speciality | Hospitalist |
Experience | 14 Years |
Location | 505 Parnassus Ave, San Francisco, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003255654 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
St Mary's Medical Center | San francisco, CA | Hospital |
Ucsf Medical Center | San francisco, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Regents Of The University Of California | 4284547274 | 563 |
News Archive
A postdoctoral researcher at the University of California, Riverside, has discovered human papillomavirus, or HPV, vaccination mandates fall short of ensuring both higher levels of uptake and equal uptake of the vaccine across socioeconomic and racial-ethnic groups.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.
Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.
› Verified 8 days ago
Entity Name | Regents Of The University Of California |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1881763597 PECOS PAC ID: 4284547274 Enrollment ID: O20031106000389 |
News Archive
A postdoctoral researcher at the University of California, Riverside, has discovered human papillomavirus, or HPV, vaccination mandates fall short of ensuring both higher levels of uptake and equal uptake of the vaccine across socioeconomic and racial-ethnic groups.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.
Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.
› Verified 8 days ago
Entity Name | University Of California San Francisco |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
A postdoctoral researcher at the University of California, Riverside, has discovered human papillomavirus, or HPV, vaccination mandates fall short of ensuring both higher levels of uptake and equal uptake of the vaccine across socioeconomic and racial-ethnic groups.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.
Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.
› Verified 8 days ago
Entity Name | Ucsf Medical Group Business Services |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
A postdoctoral researcher at the University of California, Riverside, has discovered human papillomavirus, or HPV, vaccination mandates fall short of ensuring both higher levels of uptake and equal uptake of the vaccine across socioeconomic and racial-ethnic groups.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.
Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Mauricio Jalife Bucay, MD 505 Parnassus Ave, San Francisco, CA 94143 Ph: (415) 750-4994 | Mauricio Jalife Bucay, MD 505 Parnassus Ave, San Francisco, CA 94143 Ph: (415) 750-4994 |
News Archive
A postdoctoral researcher at the University of California, Riverside, has discovered human papillomavirus, or HPV, vaccination mandates fall short of ensuring both higher levels of uptake and equal uptake of the vaccine across socioeconomic and racial-ethnic groups.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.
Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.
› Verified 8 days ago
Dr. Shannon Walker, Hospitalist Medicare: Medicare Enrolled Practice Location: 112 Parnassus Ave Apt 4, San Francisco, CA 94117 Phone: 571-271-8343 | |
Elizabeth A. Andrews, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2200 Ofarrell St, San Francisco, CA 94115 Phone: 415-833-2000 | |
Deborah Chiarucci, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2200 Ofarrell St, San Francisco, CA 94115 Phone: 415-833-2000 | |
Dr. Sneha Kemkar, Hospitalist Medicare: Medicare Enrolled Practice Location: 3700 California St, San Francisco, CA 94118 Phone: 423-309-6170 | |
Dr. Fiona Henderson, Hospitalist Medicare: Medicare Enrolled Practice Location: 3555 Cesar Chavez Street, San Francisco, CA 94110 Phone: 415-647-8600 Fax: 415-641-6823 | |
Todd A. Levine, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2200 Ofarrell St, San Francisco, CA 94115 Phone: 415-833-2000 | |
Jeannie Tran, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-476-7931 Fax: 415-476-4818 |